Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2012, Article ID 761917, 9 pages
Review Article

Target Points in Trastuzumab Resistance

National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, Tehran-Karaj HWY, Km 15, Tehran 1497716316, Iran

Received 31 October 2011; Accepted 11 November 2011

Academic Editor: Rita Nahta

Copyright © 2012 Sahar Shojaei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [11 citations]

The following is the list of published articles that have cited the current article.

  • Niels T. Foged, Anja Brugmann, and Jan T. Jorgensen, “The HER2 CISH pharmDx (TM) Kit in the assessment of breast cancer patients for anti-HER2 treatment,” Expert Review Of Molecular Diagnostics, vol. 13, no. 3, pp. 233–242, 2013. View at Publisher · View at Google Scholar
  • Yuya Nishimura, Wakiko Mimura, Izzat Fahimuddin Mohamed Suffian, Tomokazu Amino, Jun Ishii, Chiaki Ogino, and Akihiko Kondo, “Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule,” Journal Of Biochemistry, vol. 153, no. 3, pp. 251–256, 2013. View at Publisher · View at Google Scholar
  • Fikri İçli, Kadri Altundağ, Hakan Akbulut, Semra Paydaş, Gül Başaran, Pınar Saip, Gamze G. Doğu, Yeşim Eralp, Rüçhan Uslu, Alper Sevinç, Handan Onur, Nil M. Mandel, Canfeza Sezgin, Mustafa Altınbaş, Nilüfer Güler, Abdurrahman Işıkdoğan, Erhan Gökmen, Kazım Uygun, Zeki Üstüner, Arzu Yaren, Binnaz Demirkan, Uğur Coşkun, Alper Ata, Metin Özkan, and Ali Arican, “Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG),” Breast Cancer, 2013. View at Publisher · View at Google Scholar
  • Jason Mighty, Stephen Redenti, and Hsan-au Wu, “Actein induces calcium release in human breast cancer cells,” Fitoterapia, vol. 91, pp. 28–38, 2013. View at Publisher · View at Google Scholar
  • Jan Trost Jorgensen, “Companion Diagnostics in Oncology - Current Status and Future Aspects,” Oncology, vol. 85, no. 1, pp. 59–68, 2013. View at Publisher · View at Google Scholar
  • John R. Dorris, and Suzanne Jones, “Everolimus in Breast Cancer: The Role of the Pharmacist,” Annals of Pharmacotherapy, vol. 48, no. 9, pp. 1194–1201, 2014. View at Publisher · View at Google Scholar
  • Alistair Ring, Duncan Wheatley, Helen Hatcher, Robert Laing, Ruth Plummer, Martina Uttenreuther-Fischer, Graham Temple, Katy Pelling, and David Schnell, “Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer,” Clinical Cancer Research, vol. 21, no. 12, pp. 2737–2744, 2015. View at Publisher · View at Google Scholar
  • Geon-Tae Park, and Kyung-Chul Choi, “Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.,” Oncotarget, vol. 7, no. 36, pp. 58684–58695, 2016. View at Publisher · View at Google Scholar
  • Julie O’Neal, Amy Clem, Lindsey Reynolds, Susan Dougherty, Yoannis Imbert-Fernandez, Sucheta Telang, Jason Chesney, and Brian F. Clem, “Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer,” Breast Cancer Research and Treatment, 2016. View at Publisher · View at Google Scholar
  • Tetsushi Kubota, Shinji Kuroda, Nobuhiko Kanaya, Toshiaki Morihiro, Katsuyuki Aoyama, Kakiuchi Yoshihiko, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, and Toshiyoshi Fujiwara, “HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer,” Nanomedicine: Nanotechnology, Biology and Medicine, 2018. View at Publisher · View at Google Scholar
  • Anusha Ande, Tanaya R. Vaidya, Bao N. Tran, Michael Vicchiarelli, Ashley N. Brown, and Sihem Ait-Oudhia, “Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer,” Frontiers in Pharmacology, vol. 9, 2018. View at Publisher · View at Google Scholar